The association between lifestyle factors and Parkinson's disease progression and mortality.
Parkinson's disease
alcohol
coffee
cognition
progression
Journal
Movement disorders : official journal of the Movement Disorder Society
ISSN: 1531-8257
Titre abrégé: Mov Disord
Pays: United States
ID NLM: 8610688
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
received:
26
04
2018
revised:
30
07
2018
accepted:
23
08
2018
entrez:
18
1
2019
pubmed:
18
1
2019
medline:
3
1
2020
Statut:
ppublish
Résumé
Lifestyle factors may contribute to the development of Parkinson's disease, but little is known about factors that influence progression. The objective of the current study was to examine whether caffeine or alcohol consumption, physical activity, or cigarette smoking is associated with progression and survival among PD patients. We assessed lifelong coffee, tea, and alcohol consumption, smoking, and physical activity in a prospective community-based cohort (n = 360). All patients were passively followed for mortality (2001-2016); 244 were actively followed on average ± SD 5.3 ± 2.1 years (2007-2014). Movement disorder specialists repeatedly assessed motor function (Hoehn & Yahr) and cognition (Mini-Mental State Exam). We used Cox proportional hazards models and inverse probability weights to account for censoring. Coffee, caffeinated tea, moderate alcohol consumption, and physical activity were protective against at least 1 outcome. Smoking and heavy alcohol consumption were associated with increased risks. Coffee was protective against time to Hoehn & Yahr stage 3 (hazard ratio, 0.52; 95% confidence interval, 0.28-1.01), cognitive decline (hazard ratio, 0.23; 95% confidence interval, 0.11, 0.48), and mortality (hazard ratio, 0.47; 95% confidence interval, 0.32-0.69). Relative to moderate drinkers, those who never drank liquor and those who drank more heavily were at an increased risk of Hoehn & Yahr 3 (hazard ratio, 3.48; 95% confidence interval, 1.90-6.38; and hazard ratio, 2.16; 95% confidence interval, 1.03, 4.54, respectively). A history of competitive sports was protective against cognitive decline (hazard ratio, 0.46; 95% confidence interval, 0.22-0.96) and Hoehn & Yahr 3 (hazard ratio, 0.42; 95% confidence interval, 0.23-0.79), as was physical activity measured by metabolic-equivalent hours. Current cigarette smoking was associated with faster cognitive decline (hazard ratio, 3.20; 95% confidence interval, 1.02-10.01). This population-based study suggests that lifestyle factors influence PD progression and mortality. © 2019 International Parkinson and Movement Disorder Society.
Sections du résumé
BACKGROUND
Lifestyle factors may contribute to the development of Parkinson's disease, but little is known about factors that influence progression. The objective of the current study was to examine whether caffeine or alcohol consumption, physical activity, or cigarette smoking is associated with progression and survival among PD patients.
METHODS
We assessed lifelong coffee, tea, and alcohol consumption, smoking, and physical activity in a prospective community-based cohort (n = 360). All patients were passively followed for mortality (2001-2016); 244 were actively followed on average ± SD 5.3 ± 2.1 years (2007-2014). Movement disorder specialists repeatedly assessed motor function (Hoehn & Yahr) and cognition (Mini-Mental State Exam). We used Cox proportional hazards models and inverse probability weights to account for censoring.
RESULTS
Coffee, caffeinated tea, moderate alcohol consumption, and physical activity were protective against at least 1 outcome. Smoking and heavy alcohol consumption were associated with increased risks. Coffee was protective against time to Hoehn & Yahr stage 3 (hazard ratio, 0.52; 95% confidence interval, 0.28-1.01), cognitive decline (hazard ratio, 0.23; 95% confidence interval, 0.11, 0.48), and mortality (hazard ratio, 0.47; 95% confidence interval, 0.32-0.69). Relative to moderate drinkers, those who never drank liquor and those who drank more heavily were at an increased risk of Hoehn & Yahr 3 (hazard ratio, 3.48; 95% confidence interval, 1.90-6.38; and hazard ratio, 2.16; 95% confidence interval, 1.03, 4.54, respectively). A history of competitive sports was protective against cognitive decline (hazard ratio, 0.46; 95% confidence interval, 0.22-0.96) and Hoehn & Yahr 3 (hazard ratio, 0.42; 95% confidence interval, 0.23-0.79), as was physical activity measured by metabolic-equivalent hours. Current cigarette smoking was associated with faster cognitive decline (hazard ratio, 3.20; 95% confidence interval, 1.02-10.01).
CONCLUSIONS
This population-based study suggests that lifestyle factors influence PD progression and mortality. © 2019 International Parkinson and Movement Disorder Society.
Identifiants
pubmed: 30653734
doi: 10.1002/mds.27577
pmc: PMC6544143
mid: NIHMS1021811
doi:
Substances chimiques
Coffee
0
Caffeine
3G6A5W338E
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
58-66Subventions
Organisme : Veterans Administration Healthcare System (SW PADRECC)
Pays : International
Organisme : Levine Foundation
Pays : International
Organisme : NIEHS NIH HHS
ID : U54 ES012078
Pays : United States
Organisme : Parkinson Alliance
Pays : International
Organisme : National Institute of Environmental Health Science
ID : U54-ES012078
Pays : International
Organisme : NIEHS NIH HHS
ID : R01 ES010544
Pays : United States
Organisme : American Parkinson's Disease Association (APDA)
Pays : International
Organisme : National Institute of Environmental Health Science
ID : F32-ES028087
Pays : International
Organisme : NIEHS NIH HHS
ID : L30 ES029738
Pays : United States
Organisme : National Institute of Environmental Health Science
ID : R01-ES010544
Pays : International
Organisme : NIEHS NIH HHS
ID : F32 ES028087
Pays : United States
Informations de copyright
© 2019 International Parkinson and Movement Disorder Society.
Références
J Neurosci. 2001 May 15;21(10):RC143
pubmed: 11319241
J Diet Suppl. 2017 Sep 3;14(5):553-572
pubmed: 28301304
Parkinsonism Relat Disord. 2007 May;13(4):243-5
pubmed: 17275394
Mutat Res. 2010 Oct 13;692(1-2):42-8
pubmed: 20709087
Eur J Epidemiol. 2011 Jul;26(7):547-55
pubmed: 21505849
PLoS One. 2012;7(5):e36199
pubmed: 22615757
Lancet Neurol. 2016 Nov;15(12):1257-1272
pubmed: 27751556
PLoS One. 2013 Jun 19;8(6):e66452
pubmed: 23840473
J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181-4
pubmed: 1564476
Psychol Med. 2009 Jan;39(1):3-11
pubmed: 18570697
Neurology. 1998 Feb;50(2):318 and 16 pages following
pubmed: 9484345
Br J Sports Med. 2012 Mar;46(4):291-5
pubmed: 21459873
Arch Intern Med. 2006 Dec 11-25;166(22):2437-45
pubmed: 17159008
Eur J Nutr. 2016 Jun;55(4):1331-43
pubmed: 26932503
Arch Clin Neuropsychol. 2005 Jun;20(4):485-503
pubmed: 15896562
Clin Neuropharmacol. 2008 Jul-Aug;31(4):189-96
pubmed: 18670242
Neurology. 2017 Oct 24;89(17):1802
pubmed: 28954875
Public Health Nutr. 2015 May;18(7):1282-91
pubmed: 25089347
Int J Geriatr Psychiatry. 1998 Oct;13(10):661-6
pubmed: 9818300
Parkinsonism Relat Disord. 2016 Jul;28:112-7
pubmed: 27177695
Int J Epidemiol. 2011 Oct;40(5):1382-400
pubmed: 22039197
J Neurol Neurosurg Psychiatry. 2007 Dec;78(12):1298-303
pubmed: 17442763
Mov Disord. 2004 Sep;19(9):1087-1092
pubmed: 15372603
J Clin Neurol. 2015 Jul;11(3):212-9
pubmed: 26174783
Am J Epidemiol. 2009 Apr 15;169(8):919-26
pubmed: 19270050
J Parkinsons Dis. 2016 Oct 19;6(4):685-698
pubmed: 27567884
BMC Cancer. 2011 Mar 15;11:96
pubmed: 21406107
Neuroreport. 2013 Jul 10;24(10):509-14
pubmed: 23636255
Ann Neurol. 2002 Sep;52(3):276-84
pubmed: 12205639
Mov Disord. 2008 Apr 15;23(5):631-40
pubmed: 18181210
Neurology. 2014 Oct 14;83(16):1396-402
pubmed: 25217056
J Nutr Health Aging. 2015 Mar;19(3):313-28
pubmed: 25732217